Almost 11 years after the suit was filed, a Delaware court has dismissed a class action against AstraZeneca over its alleged consumer fraud in the marketing of heartburn medication Nexium.
Superior Court Judge Vivian L. Medinilla said there was just not enough evidence to show that the plaintiffs—a group of four New York-based health care funds—relied on any alleged misrepresentation by AstraZeneca that Nexium was a better drug than the over-the-counter version of Prilosec.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
